The cell & gene therapy (CGT) CDMO has an established global footprint with two GMP manufacturing facilities in China and its headquarters in Vancouver...
Next&Bio has teamed up with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to establish ...
GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, has expanded its primary manufacturing facil...
WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. InflaRx received emerge...
"We are very pleased to achieve full patient enrollment in Asia ahead of schedule, which brings Everest an important step closer to offering etrasimod to p...
Transcenta in-licensed the Great China rights of Blosozumab from Eli Lilly and Company ("Eli Lilly") for development and commercialization in Greater China...
With around 5,000 global manufacturers spanning the healthcare supply chain, the CMEF organized by Reed Sinopharm Exhibitions is unparalleled in its scale,...
During the conference’s poster session, OliX revealed preclinical study results of OLX702A, addressing key mechanisms involved in NASH and obesity. T...
The collaboration agreement combines Angelini Pharma’s expertise in neurological diseases with JCR Pharmaceuticals’ scientific and technologi...
OliX participated in the ‘Korea-US Digital·BioHealth Business Forum’ hosted by the South Korean Ministry of Health and Welfare and Kor...
On March 31, 2023, the government of the Hong Kong Special Administrative Region announced that, from April 20, high-risk groups will be able to receive fr...
Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access...
This is the seventh NMPA-approved indication of TYVYT® (sintilimab injection). The first six indications of TYVYT® (sintilimab injection) are inclu...
Under the terms of the agreement, Acorda will receive an up-front payment of $2.5 million, a near term milestone payment of up to $6 million, $3 million up...
© 2024 Biopharma Boardroom. All Rights Reserved.
